510(k) · Cleared
ClearedDelfia Neonatal Thyroxine Kit
Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly
Wallac OY · CDX Radioimmunoassay, Total Thyroxine
Cleared on Mar 10, 1995 after a 238-day review. FDA lists a 510(k) statement for it but has not posted the file, so its predicates are not known. 1 later device descends from it.
- Decided
- Mar 10, 1995
- Review
- 238 days
- Class
- Class II
- Product code
- CDX
- Recalls
- None
- Predicates
- 0
1 later device descends from it, 1 citing it directly.
- This deviceK943416 Delfia Neonatal Thyroxine KitWallac OY · 1995
- Descendant · cites it directly · 0 of its ownK103484 GSP Neonatal Thyroxine (T4)Wallac Oy, A Subsidiary of Perkinelmer, Inc. · 2011
Most influential descendants
Showing 1 of 1 · See all- K103484GSP Neonatal Thyroxine (T4)Wallac Oy, A Subsidiary of Perkinelmer, Inc. · 2011 · cites it directly0descendants
View FIG. 1 as a table
Line of descent and top descendants
| Generation | Number | Device | Applicant | Decided | Recalls |
|---|---|---|---|---|---|
| 0 (this device) | K943416 | Delfia Neonatal Thyroxine Kit | Wallac OY | 1995 | — |
| +1 | K103484 | GSP Neonatal Thyroxine (T4) | Wallac Oy, A Subsidiary of Perkinelmer, Inc. | 2011 | — |
Descendants by year cleared
| Year cleared | Devices | With a Class I recall |
|---|---|---|
| 2011 | 1 | 0 |
Sources: FDA 510(k) database (decision fields), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.
Planning a device in CDX? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.
- Candidate predicates for a device like this, rankedin the report
- Recall history across each candidate’s familyin the report
What was it cleared against?
FDA lists a 510(k) statement for it but has not posted the file, so its predicates are not known.
What descends from it? (1)
1 later device cites it directly; ranked here by how many devices descend from each in turn.
| Number | Device | Decided | Descendants |
|---|---|---|---|
| K103484 | GSP Neonatal Thyroxine (T4) | 2011 | 0 |
Has anything in its family been recalled? (0 Class I)
No FDA recall names this device.
No ancestor or descendant has a Class I recall.
What does this lineage say?
- Of its descendants, K103484 (Wallac Oy, A Subsidiary of Perkinelmer, Inc., 2011) has gone furthest, with 0 descendants of its own.
How does its category compare?
All CDX devicesCDX Radioimmunoassay, Total Thyroxine: FDA decisions, review times, recalls and adverse event reports over 20 years.
FDA decisions per year · CDX
FDA has decided no CDX device since 2007.
Median 510(k) review, days · CDX
Too few CDX 510(k)s in any year since 2007 to give a median.
Recalls per year · CDX
No recall names CDX since 2007.
Adverse event reports per year · CDX
8in 2025
MAUDE reports naming product code CDX, not matched to any one device; reports are not rates.
View these four charts as a table
| Year | Decisions | Median 510(k) review, days | Recalls (Class I) | MAUDE reports |
|---|---|---|---|---|
| 2007 | 0 | — | 0 | 0 |
| 2008 | 0 | — | 0 | 0 |
| 2009 | 0 | — | 0 | 0 |
| 2010 | 0 | — | 0 | 0 |
| 2011 | 0 | — | 0 | 6 |
| 2012 | 0 | — | 0 | 1 |
| 2013 | 0 | — | 0 | 0 |
| 2014 | 0 | — | 0 | 4 |
| 2015 | 0 | — | 0 | 5 |
| 2016 | 0 | — | 0 | 4 |
| 2017 | 0 | — | 0 | 7 |
| 2018 | 0 | — | 0 | 14 |
| 2019 | 0 | — | 0 | 7 |
| 2020 | 0 | — | 0 | 5 |
| 2021 | 0 | — | 0 | 2 |
| 2022 | 0 | — | 0 | 7 |
| 2023 | 0 | — | 0 | 12 |
| 2024 | 0 | — | 0 | 8 |
| 2025 | 0 | — | 0 | 8 |
| 2026 | 0 | — | 0 | — |
https://510kreport.com/device/K943416 · printed Nov 5, 2026
Cite this page
510(k) Report. “K943416: Delfia Neonatal Thyroxine Kit.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 5, 2026. https://510kreport.com/device/K943416
Report an extraction error
Are you the manufacturer?
Record history
- FDA decision record loaded May 2, 2026
- Lineage and recalls computed Nov 3, 2026
- Page last updated Nov 3, 2026